(Q42380386)

English

Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer

scientific article published on April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 October 2017

Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer (English)

1 reference

Europe PubMed Central

28 October 2017

1 reference

based on heuristic

inferred from title

3

object named as

George Wilding

1 reference

Europe PubMed Central

28 October 2017

author name string

Steven Attia

1

1 reference

Europe PubMed Central

28 October 2017

Jens Eickhoff

2

1 reference

Europe PubMed Central

28 October 2017

Douglas McNeel

4

1 reference

Europe PubMed Central

28 October 2017

Jules Blank

5

1 reference

Europe PubMed Central

28 October 2017

Harish Ahuja

6

1 reference

Europe PubMed Central

28 October 2017

Alcee Jumonville

7

1 reference

Europe PubMed Central

28 October 2017

Michael Eastman

8

1 reference

Europe PubMed Central

28 October 2017

Daniel Shevrin

9

1 reference

Europe PubMed Central

28 October 2017

Michael Glode

10

1 reference

Europe PubMed Central

28 October 2017

Dona Alberti

11

1 reference

Europe PubMed Central

28 October 2017

Mary Jane Staab

12

1 reference

Europe PubMed Central

28 October 2017

Dottie Horvath

13

1 reference

Europe PubMed Central

28 October 2017

Jane Straus

14

1 reference

Europe PubMed Central

28 October 2017

Rebecca Marnocha

15

1 reference

Europe PubMed Central

28 October 2017

Glenn Liu

16

1 reference

Europe PubMed Central

28 October 2017

language of work or name

0 references

publication date

1 April 2008

1 reference

Europe PubMed Central

28 October 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

28 October 2017

14

1 reference

Europe PubMed Central

28 October 2017

8

1 reference

Europe PubMed Central

28 October 2017

2437-2443

1 reference

Europe PubMed Central

28 October 2017

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24‐dihydroxyvitamin D2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Comparative review of the pharmacokinetics of vitamin D analogues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

1 alpha,24(S)-dihydroxyvitamin D2: a biologically active product of 1 alpha-hydroxyvitamin D2 made in the human hepatoma, Hep3B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

28 May 2018

Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648051

16 August 2018

1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitamin D and prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/18413835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-07-4274

1 reference

Europe PubMed Central

28 October 2017

release_nfebq56fivbznja7yjidceorny

1 reference

https://api.fatcat.wiki/v0/release/nfebq56fivbznja7yjidceorny

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

28 October 2017

1 reference

Europe PubMed Central

28 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42380386&oldid=1943165861"